A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin’s lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments. …
Source:Nivolumab drug highly effective for Hodgkin’s lymphoma
Sunday, December 7, 2014
Nivolumab drug highly effective for Hodgkin’s lymphoma
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment